知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

169 条记录 (耗时 0.033 秒)

    MIXED BACTERIA PRODUCING BIOSURFACTANT AND ITS SCREENING METHOD
    2.
    发明申请
    MIXED BACTERIA PRODUCING BIOSURFACTANT AND ITS SCREENING METHOD 审中-公开
    生产生物物质的混合细菌及其筛选方法

    公开(公告)号：US20160347989A1

    公开(公告)日：2016-12-01

    申请号：US15141349

    申请日：2016-04-28

    申请人： ZFA Technologies Inc.

    发明人： Hao DUAN

    IPC分类号： C09K8/584 ,  C12Q1/02 ,  C12N1/20

    CPC分类号： C09K8/584 ,  C09K8/582 ,  C12N1/20 ,  C12Q1/64 ,  G01N2333/21 ,  G01N2333/32 ,  G01N2333/355

    摘要： Embodiments of the invention relate to a mixed bacteria producing surfactant and its screening method. According to at least one embodiment, there is provided a mixed bacteria producing biosurfactant composed of three kinds of strains: Pseudomonas stutzeri with preservation No. CCTCC AB 205091, Nocardioides ginsengagri with preservation No. CCTCC S2013441, and Bacillus licheniformis with preservation No. CCTCC AB 205141. The mixed bacteria is obtained by choosing the bacterial strain for oil production awaiting screening, activating and culturing it, getting the fermentation liquid in primary screen with blood plate method, and re-screening fermentation liquid in primary screen with oil drain method. This mixed bacteria synthesizes the advantages of the three strain, thus producing a biosurfactant to enhance oil recovery in the oilfield. The screening method of this mixed bacteria has a broad scope of applications, which effectively reduce the screening cost with high accuracy, provides strong selectivity, is a convenient process and easy to operate, and has a shorter cycle compared with the current technology.

    摘要翻译： 本发明的实施方案涉及混合细菌生产表面活性剂及其筛选方法。 根据至少一个实施方案，提供了由三种菌株组成的混合细菌生产生物表面活性剂：具有保藏号CCTCC AB 205091的保护性假单胞菌，具有保藏号CCTCC S2013441的诺卡氏菌Ginsengagri和保藏号CCTCC AB的地衣芽孢杆菌 混合细菌通过选择用于生产油的细菌菌株进行筛选，活化和培养，使用血版法获得初筛液中的发酵液，并用排油法重新筛选初筛中的发酵液。 这种混合细菌合成了三种菌株的优点，从而生产出一种生物表面活性剂，以提高油田的油回收率。 这种混合细菌的筛选方法应用范围广，可以高精度有效降低筛选成本，提供强选择性，操作方便，操作方便，与现有技术相比具有更短的循环寿命。

    SYNTHETIC OLIGOSACCHARIDES FOR P. AERUGINOSA VACCINE
    4.
    发明申请
    SYNTHETIC OLIGOSACCHARIDES FOR P. AERUGINOSA VACCINE 审中-公开
    阿维菌素疫苗的合成寡糖

    公开(公告)号：US20160144016A1

    公开(公告)日：2016-05-26

    申请号：US14902218

    申请日：2014-07-01

    申请人： SYNGLYCO PHARMACEUTICALS, INC.

    发明人： A. Stewart Campbell ,  Obadiah Joseph Plante

    IPC分类号： A61K39/104 ,  G01N33/569 ,  C07K16/12

    CPC分类号： A61K39/104 ,  C07H13/04 ,  C07H15/04 ,  C07K16/1214 ,  C07K16/44 ,  C07K2317/24 ,  C07K2317/622 ,  G01N33/56911 ,  G01N2333/21 ,  G01N2469/10

    摘要： The present invention provides synthetic Pseudomonas aeruginosa lipooligosaccharide (LOS)-based oligosaccharides and conjugates containing various P. aeruginosa serotype-specific oligosaccharide antigens or various core P. aeruginosa oligosaccharide structures or motifs. The invention further provides P. aeruginosa LOS-based immunogenic and immunoprotective compositions and antibodies derived therefrom for diagnosing, treating, and preventing infections caused by P. aeruginosa.

    摘要翻译： 本发明提供合成的铜绿假单胞菌脂寡糖（LOS）基寡糖和含有各种铜绿假单胞菌血清型特异性寡糖抗原或各种核心铜绿假单胞菌寡糖结构或基序的缀合物。 本发明还提供了铜绿假单胞菌LOS基的免疫原性和免疫保护组合物及其衍生的抗体用于诊断，治疗和预防由铜绿假单胞菌引起的感染。

    Method of diagnosing and treating melioidosis
    6.
    发明授权
    Method of diagnosing and treating melioidosis 有权
    诊断和治疗恶病质的方法

    公开(公告)号：US09310365B2

    公开(公告)日：2016-04-12

    申请号：US13639450

    申请日：2011-04-12

    申请人： Thomas Kozel ,  David Aucoin

    发明人： Thomas Kozel ,  David Aucoin

    IPC分类号： G01N33/569 ,  C07K16/12

    CPC分类号： G01N33/56911 ,  C07K16/1214 ,  G01N2333/21 ,  G01N2800/52

    摘要： Non-invasive methods are provided herein for the diagnosis of melioidosis with specific antibodies capable of detecting molecules associated with melioidosis in a biological fluid, such as urine or serum. These molecules can be identified using proteomic methods, including but not limited to antibody based methods, such as an enzyme-linked immunosorbant assay (ELISA), a radioimmunoassay (RIA), or a lateral flow immunoassay. Methods of inducing an immune response to melioidosis are also disclosed. The methods include the use of the immunogenic melioidosis polypeptides, nucleic acids encoding these polypeptides, and/or viral vectors encoding an immunogenic melioidosis polypeptide, alone or in conjunction with other agents, such as traditional melioidosis therapies. Also disclosed are methods for treating a subject having melioidosis. These methods include inducing an immune response to melioidosis and/or using an inhibitory nucleic acid, such as a siRNA or antisense molecule, to decrease a melioidosis associated molecule expression in order to treat melioidosis.

    摘要翻译： 本文提供了非侵入性方法，用于诊断具有能够检测与生物流体例如尿液或血清中的黑素综合征有关的分子的特异性抗体的嗜酸性粒细胞减少症。 可以使用蛋白质组学方法鉴定这些分子，包括但不限于基于抗体的方法，例如酶联免疫吸附测定（ELISA），放射免疫测定（RIA）或侧流免疫测定。 还公开了诱导对嗜酸性粒细胞减少症的免疫应答的方法。 所述方法包括单独使用免疫原性黑麦病多糖，编码这些多肽的核酸和/或编码免疫原性黑麦病多肽的病毒载体，或与其它试剂例如传统的黑素综合征疗法联合使用。 还公开了用于治疗患有黑痴病的受试者的方法。 这些方法包括诱导针对嗜酸性粒细胞减少症的免疫应答和/或使用抑制性核酸如siRNA或反义分子来降低与相似的分子表达的melioidosis相关的分子表达以治疗黑麦病。

    METHODS FOR THE IDENTIFICATION OF ANTIBIOTICS THAT ARE NOT SUSCEPTIBLE TO ANTIBIOTIC RESISTANCE IN PSEUDOMONAS AERUGINOSA
    7.
    发明申请
    METHODS FOR THE IDENTIFICATION OF ANTIBIOTICS THAT ARE NOT SUSCEPTIBLE TO ANTIBIOTIC RESISTANCE IN PSEUDOMONAS AERUGINOSA 有权
    鉴定抗精神病药物的方法不能抵抗PSEUDOMONAS AERUGINOSA的抗生素耐药性

    公开(公告)号：US20150284765A1

    公开(公告)日：2015-10-08

    申请号：US14746043

    申请日：2015-06-22

    申请人： Wayne State University

    发明人： Philip R. Cunningham

    IPC分类号： C12Q1/18 ,  C12Q1/10 ,  C12Q1/68

    CPC分类号： C12Q1/18 ,  C12N15/1034 ,  C12N15/1086 ,  C12N15/67 ,  C12N15/70 ,  C12Q1/025 ,  C12Q1/10 ,  C12Q1/6876 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N2333/21 ,  G01N2500/10

    摘要： The “instant evolution” system was initially developed in E. coli, primarily because of the ease with which this organism can be genetically manipulated. Because many of the functionally important regions of rRNA are conserved among bacteria, drug leads developed against conserved targets in the E. coli system may produce broad-spectrum anti-infectives. In order to develop a system to produce narrow-spectrum anti-infectives, herein we disclose methods for identifying functional mutant P. aeruginosa ribosomes suitable as drug targets and for identifying drug candidates that do not bind to the human 16S rRNA.

    摘要翻译： “即时演化”系统最初是在大肠杆菌中开发的，主要是因为这种生物体易于被遗传操纵。 由于rRNA的许多功能重要区域在细菌中是保守的，所以在大肠杆菌系统中针对保守靶标产生的药物靶点可能产生广谱抗感染剂。 为了开发生产窄谱抗感染药物的系统，本文公开了用于鉴定适合作为药物靶标的功能性突变铜绿假单胞菌核糖体的方法，以及鉴定不结合人16S rRNA的候选药物。